- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00424294
A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis
10 september 2014 bijgewerkt door: Pfizer
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of CP-195543 And Celecoxib Dual Therapy In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis In Subjects Who Are Inadequately Controlled On Methotrexate
To evaluate the efficacy, safety and tolerability of CP-195543 and celecoxib dual therapy in subjects with rheumatoid arthritis
Studie Overzicht
Toestand
Beëindigd
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Trial enrollment was prematurely discontinued on December 3, 2007.
The results of an interim efficacy and safety analysis demonstrated an overall poor tolerability profile and high discontinuation rate when dual therapy with CP-195543 and Celecoxib was administered.
The decision to discontinue further enrollment in the trial was not based on any efficacy or serious safety concerns.
Previously enrolled study participants continued in the study and the trial completed on February 27, 2008.
Studietype
Ingrijpend
Inschrijving (Werkelijk)
70
Fase
- Fase 2
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Alabama
-
Huntsville, Alabama, Verenigde Staten, 35801
- Pfizer Investigational Site
-
-
Arizona
-
Scottsdale, Arizona, Verenigde Staten, 85251
- Pfizer Investigational Site
-
-
California
-
Upland, California, Verenigde Staten, 91786
- Pfizer Investigational Site
-
-
Florida
-
Boca Raton, Florida, Verenigde Staten, 33486
- Pfizer Investigational Site
-
Clearwater, Florida, Verenigde Staten, 33765
- Pfizer Investigational Site
-
Dunedin, Florida, Verenigde Staten, 34698
- Pfizer Investigational Site
-
Fort Lauderdale, Florida, Verenigde Staten, 33334
- Pfizer Investigational Site
-
Lake Mary, Florida, Verenigde Staten, 32746
- Pfizer Investigational Site
-
Miramar, Florida, Verenigde Staten, 33025
- Pfizer Investigational Site
-
New Port Richey, Florida, Verenigde Staten, 34652
- Pfizer Investigational Site
-
Orange City, Florida, Verenigde Staten, 32763
- Pfizer Investigational Site
-
Orlando, Florida, Verenigde Staten, 32804
- Pfizer Investigational Site
-
Port Richey, Florida, Verenigde Staten, 34668
- Pfizer Investigational Site
-
Sarasota, Florida, Verenigde Staten, 34233
- Pfizer Investigational Site
-
Sarasota, Florida, Verenigde Staten, 34239
- Pfizer Investigational Site
-
Tampa, Florida, Verenigde Staten, 33614-7118
- Pfizer Investigational Site
-
Venice, Florida, Verenigde Staten, 34292
- Pfizer Investigational Site
-
Vero Beach, Florida, Verenigde Staten, 32960
- Pfizer Investigational Site
-
-
Illinois
-
Moline, Illinois, Verenigde Staten, 61265
- Pfizer Investigational Site
-
Springfield, Illinois, Verenigde Staten, 62704
- Pfizer Investigational Site
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46250
- Pfizer Investigational Site
-
Munster, Indiana, Verenigde Staten, 46321
- Pfizer Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40504
- Pfizer Investigational Site
-
-
Louisiana
-
Covington, Louisiana, Verenigde Staten, 70433
- Pfizer Investigational Site
-
New Orleans, Louisiana, Verenigde Staten, 70115
- Pfizer Investigational Site
-
-
Maryland
-
Frederick, Maryland, Verenigde Staten, 21702
- Pfizer Investigational Site
-
-
Michigan
-
Kalamazoo, Michigan, Verenigde Staten, 49009
- Pfizer Investigational Site
-
-
Mississippi
-
Tupelo, Mississippi, Verenigde Staten, 38801
- Pfizer Investigational Site
-
-
Missouri
-
Springfield, Missouri, Verenigde Staten, 65807
- Pfizer Investigational Site
-
-
New York
-
Olean, New York, Verenigde Staten, 14760
- Pfizer Investigational Site
-
Rochester, New York, Verenigde Staten, 14618
- Pfizer Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73139
- Pfizer Investigational Site
-
-
Pennsylvania
-
Philladelphia, Pennsylvania, Verenigde Staten, 19118
- Pfizer Investigational Site
-
-
Tennessee
-
Knoxville, Tennessee, Verenigde Staten, 37909-1600
- Pfizer Investigational Site
-
Memphis, Tennessee, Verenigde Staten, 38119
- Pfizer Investigational Site
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77090
- Pfizer Investigational Site
-
Killeen, Texas, Verenigde Staten, 76549
- Pfizer Investigational Site
-
San Antonio, Texas, Verenigde Staten, 78217
- Pfizer Investigational Site
-
-
Utah
-
Ogden, Utah, Verenigde Staten, 84403
- Pfizer Investigational Site
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- A diagnosis of RA based upon the American college of Rheumatology 1987 revised criteria
- Active disease at Screening
- Stable dose of methotrexate between 10-25 mg/week oral or parenteral
Exclusion Criteria:
- A diagnosis of any other inflammatory or secondary, noninflammatory arthritis that, in the opinion of the Investigator, would interfere with disease activity assessments
- A history of hypersensitivity or allergic type reactions to cyclooxygenase inhibitors, opiates, aspirin or sulfonamides
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: Celecoxib
Celecoxib with placebo therapy.
|
Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States [US] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
|
Ander: Methotrexate
Background Methotrexate taken in both CP-195,543/Celecoxib and Celecoxib only arms.
|
Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
|
Experimenteel: CP-195,543
CP-195,543 and Celecoxib dual therapy.
|
CP-195543 is a potent and specific antagonist of the leukotriene B4 (LTB4) receptor.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12
Tijdsspanne: Week 12
|
ACR20 response: greater than or equal to (>=) 20 percent (%) improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
|
Week 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 1, 2, 4 and 8
Tijdsspanne: Week 1, 2, 4, 8
|
ACR20 response: >=20% improvement in tender joint count; >=20% improvement in swollen joint count; and >=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
|
Week 1, 2, 4, 8
|
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response
Tijdsspanne: Week 1, 2, 4, 8, 12
|
ACR50 response: >=50% improvement in tender joint count; >=50% improvement in swollen joint count; and >=50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
|
Week 1, 2, 4, 8, 12
|
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
Tijdsspanne: Week 1, 2, 4, 8, 12
|
ACR70 response: >=70% improvement in tender joint count; >=70% improvement in swollen joint count; and >=70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).
|
Week 1, 2, 4, 8, 12
|
Change From Baseline in Tender/Painful Joint Count (TJC) at Week 1, 2, 4, 8 and 12
Tijdsspanne: Baseline, Week 1, 2, 4, 8, 12
|
Participants were assessed for tender/painful joints using a 28-joint count comprised of left and right shoulders, elbows, wrists, proximal interphalangeal joints, metacarpophalangeal joints and knees.
Artificial joints were not assessed.
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in Swollen Joint Count (SJC) at Week 1, 2, 4, 8 and 12
Tijdsspanne: Baseline, Week 1, 2, 4, 8, 12
|
Participants were assessed for swollen joints using a 28-joint count comprised of left and right shoulders, elbows, wrists, proximal interphalangeal joints, metacarpophalangeal joints and knees.
Artificial joints were not assessed.
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in Patient's Assessment of Arthritis Pain at Week 1, 2, 4, 8 and 12
Tijdsspanne: Baseline, Week 1, 2, 4, 8, 12
|
Patient's assessment of arthritis pain was assessed using a 100 millimeter (mm) visual analogue scale (VAS) with range: 0 = no pain to 100 = worst possible pain.
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in Patient's Global Assessment of Arthritis at Week 1, 2, 4, 8 and 12
Tijdsspanne: Baseline, Week 1, 2, 4, 8, 12
|
Patient's global assessment of arthritic condition assessed all the ways participants' illness and health conditions affect them at the time of assessment.
The response was scored on a 5-point scale: 1 = Very Good (Asymptomatic and no limitation of normal activities), 2 = Good (Mild symptoms and no limitation of normal activities), 3 = Fair (Moderate symptoms and limitation of some normal activities), 4 = Poor (Severe symptoms and inability to carry out most normal activities) and 5 = Very Poor (Very severe symptoms which are intolerable and inability to carry out all normal activities).
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in Physician's Global Assessment of Arthritis at Week 1, 2, 4, 8 and 12
Tijdsspanne: Baseline, Week 1, 2, 4, 8, 12
|
Investigator assessed overall appearance of arthritis at the time of the visit.
The response was scored on a 5-point scale: 1 = Very Good (Asymptomatic and no limitation of normal activities), 2 = Good (Mild symptoms and no limitation of normal activities), 3 = Fair (Moderate symptoms and limitation of some normal activities), 4 = Poor (Severe symptoms and inability to carry out most normal activities) and 5 = Very Poor (Very severe symptoms which are intolerable and inability to carry out all normal activities).
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 1, 2, 4, 8 and 12
Tijdsspanne: Baseline, Week 1, 2, 4, 8, 12
|
Health Assessment Questionnaire-Disability Index (HAQ-DI): participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week.
Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do.
Overall score was computed as the sum of domain scores and divided by the number of domains answered.
Total possible score range 0-3, where 0 = least difficulty and 3 = extreme difficulty.
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in C-Reactive Protein (CRP) at Week 1, 2, 4, 8 and 12
Tijdsspanne: Baseline, Week 1, 2, 4, 8, 12
|
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay.
A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 1, 2, 4, 8 and 12
Tijdsspanne: Baseline, Week 1, 2, 4, 8, 12
|
DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP.
It was calculated as DAS28-3 (CRP) = 1.15 + 1.10 * ([0.56 * square root of TJC] + [0.28 * square root of SJC] + [0.36 * natural logarithm of {CRP+1}]).
Total score range: 0 to 9.4, higher score indicated more disease activity.
DAS28-3 (CRP) <= 3.2 implied low disease activity and >3.2 to 5.1 implied moderate to high disease activity, and DAS28-3 (CRP) <2.6 = remission.
|
Baseline, Week 1, 2, 4, 8, 12
|
Change From Baseline in Duration of Morning Stiffness at Week 1, 2, 4, 8 and 12
Tijdsspanne: Baseline, Week 1, 2, 4, 8, 12
|
Duration of morning stiffness was defined as the time elapsed between the time participant woke up and was able to resume normal activities without stiffness in hours (duration was recorded in hours to the nearest quarter.
For those participants with unrelenting stiffness, duration was recorded as 24 hours).
|
Baseline, Week 1, 2, 4, 8, 12
|
Number of Participants Who Withdrew From Study Due to Lack of Efficacy
Tijdsspanne: Baseline up to Week 12
|
Baseline up to Week 12
|
|
Time to Withdrawal Due to Lack of Efficacy
Tijdsspanne: Baseline up to Week 12
|
Baseline up to Week 12
|
|
Number of Participants With Clinical Laboratory Abnormalities
Tijdsspanne: Baseline up to Week 13
|
Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, lactate dehydrogenase, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium, phosphate, bicarbonate); clinical chemistry (glucose, creatine kinase); immunology (CRP); urinalysis (dipstick [urine specific gravity, decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, bilirubin], microscopy [urine RBC, WBC, urate crystals, calcium, oxalate, miscellaneous [urine mucus and leucocytes]).
|
Baseline up to Week 13
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tijdsspanne: Baseline up to 28 days after last dose
|
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
|
Baseline up to 28 days after last dose
|
Number of Adverse Events by Severity
Tijdsspanne: Baseline up to 28 days after last dose
|
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug.
AEs are classified according to the severity in 3 categories a) mild - AEs does not interfere with participant's usual function b) moderate - AEs interferes to some extent with participant's usual function c) severe - AEs interferes significantly with participant's usual function.
|
Baseline up to 28 days after last dose
|
Change From Baseline in Systolic and Diastolic Blood Pressure at Day 7, 14, 21, 28, 42, 56, 84 and 91
Tijdsspanne: Baseline, Day 7, 14, 21, 28, 42, 56, 84, 91
|
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were evaluated in sitting position.
|
Baseline, Day 7, 14, 21, 28, 42, 56, 84, 91
|
Change From Baseline in Heart Rate Day 7, 14, 21, 28, 42, 56, 84 and 91
Tijdsspanne: Baseline, Day 7, 14, 21, 28, 42, 56, 84, 91
|
Baseline, Day 7, 14, 21, 28, 42, 56, 84, 91
|
|
Number of Participants With Abnormal Electrocardiogram (ECG)
Tijdsspanne: Baseline up to Week 12
|
Criteria for potential clinical concern in ECG parameters: Maximum corrected QT interval (QTc) in range of 450 to less than 480 millisecond (msec), Maximum QTcB interval (Bazett's Correction) (msec) in range of 450 to less than 480 msec, Maximum QTcF interval (Fridericia's Correction) in range of 450 to less than 480 msec, maximum QTc interval increase from baseline in range of 30 to less than 60 msec and >=60 msec.
|
Baseline up to Week 12
|
Number of Participants With Categorical Vital Signs Data
Tijdsspanne: Baseline, Week 12
|
Number of participants with maximum increase from Baseline in sitting SBP and DBP of greater than or equal to 30 mmHg at Week 12 was reported.
|
Baseline, Week 12
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start
1 juni 2006
Primaire voltooiing (Werkelijk)
1 december 2007
Studie voltooiing (Werkelijk)
1 februari 2008
Studieregistratiedata
Eerst ingediend
18 januari 2007
Eerst ingediend dat voldeed aan de QC-criteria
18 januari 2007
Eerst geplaatst (Schatting)
19 januari 2007
Updates van studierecords
Laatste update geplaatst (Schatting)
25 september 2014
Laatste update ingediend die voldeed aan QC-criteria
10 september 2014
Laatst geverifieerd
1 september 2014
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het immuunsysteem
- Auto-immuunziekten
- Gewrichtsziekten
- Musculoskeletale aandoeningen
- Reumatische aandoeningen
- Bindweefselziekten
- Artritis
- Artritis, reumatoïde
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Agenten van het perifere zenuwstelsel
- Nucleïnezuursyntheseremmers
- Enzymremmers
- Pijnstillers
- Sensorische systeemagenten
- Ontstekingsremmers, niet-steroïde
- Pijnstillers, niet-narcotisch
- Ontstekingsremmende middelen
- Antireumatische middelen
- Cyclo-oxygenaseremmers
- Antimetabolieten, antineoplastische
- Antimetabolieten
- Antineoplastische middelen
- Immunosuppressieve middelen
- Immunologische factoren
- Dermatologische middelen
- Reproductieve controlemiddelen
- Cyclo-oxygenase 2-remmers
- Afbrekende middelen, niet-steroïde
- Abortieve agenten
- Foliumzuurantagonisten
- Celecoxib
- Methotrexaat
Andere studie-ID-nummers
- A7701005
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Artritis, reumatoïde
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital of Zhejiang Chinese Medical University; Zhejiang...Werving
-
Texas Tech University Health Sciences Center, El...Beëindigd
-
Nantes University HospitalVoltooidSeptische arthritisFrankrijk
-
wangxiaodongVoltooid
-
Second Affiliated Hospital, School of Medicine,...VoltooidSeptische arthritisChina
-
Rennes University HospitalVoltooid
-
Assiut UniversityNog niet aan het wervenSeptische arthritis
-
Assiut UniversityNog niet aan het werven
-
Assistance Publique - Hôpitaux de ParisWerving
-
Khoo Teck Puat HospitalOnbekend
Klinische onderzoeken op celecoxib
-
Chong Kun Dang PharmaceuticalVoltooidArtrose handKorea, republiek van
-
Hoffmann-La RocheVoltooidReumatoïde artritisRussische Federatie
-
Samsung Medical CenterThe Korean Urological AssociationIngetrokkenGoedaardige prostaathyperplasieKorea, republiek van
-
Yooyoung Pharmaceutical Co., Ltd.CliPS Co., LtdVoltooidArtrose, knieKorea, republiek van
-
Seoul National University HospitalVoltooid
-
Targeted Therapy Technologies, LLCWervingMacula-oedeem | Epiretinaal membraan | Tak Retinale Ader Occlusie | Stralingsretinopathie | Centrale sereuze retinopathie met putje van optische schijf | Commotio Retinae | VitritisVerenigde Staten
-
Seoul National University HospitalVoltooidHersenbloedingKorea, republiek van
-
Dr. Reddy's Laboratories LimitedVoltooidAcute pijnVerenigde Staten
-
Peking University Third HospitalNog niet aan het werven
-
Xintian PharmaceuticalNog niet aan het werven